Assembly Biosciences, Inc.

DB:V7B Stock Report

Market Cap: €515.1m

Assembly Biosciences Management

Management criteria checks 2/4

Assembly Biosciences' CEO is Jason Okazaki, appointed in Aug 2022, has a tenure of 3.25 years. total yearly compensation is $1.77M, comprised of 35.4% salary and 64.6% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth €459.44K. The average tenure of the management team and the board of directors is 4.1 years and 4.8 years respectively.

Key information

Jason Okazaki

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage35.44%
CEO tenure3.3yrs
CEO ownership0.09%
Management average tenure4.1yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Okazaki's remuneration changed compared to Assembly Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$39m

Jun 30 2025n/an/a

-US$39m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$2mUS$626k

-US$40m

Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$1mUS$600k

-US$61m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$2mUS$555k

-US$93m

Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$127m

Mar 31 2022n/an/a

-US$126m

Dec 31 2021US$1mUS$533k

-US$130m

Sep 30 2021n/an/a

-US$109m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$4mUS$394k

-US$62m

Compensation vs Market: Jason's total compensation ($USD1.77M) is above average for companies of similar size in the German market ($USD1.04M).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.

CEO

Jason Okazaki (49 yo)

3.3yrs
Tenure
US$1,767,191
Compensation

Mr. Jason A. Okazaki serves as Chief Executive Officer and Director at Assembly Biosciences, Inc. since January 01, 2023. He served as Chief Operating Officer of Assembly Biosciences, Inc. since August 1,...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Okazaki
CEO, President & Director3.3yrsUS$1.77m0.089%
€ 459.4k
William Delaney
Chief Scientific Officer5.5yrsUS$963.47k0.10%
€ 521.3k
Nicole White
Chief Manufacturing Officer5yrsUS$827.54k0.049%
€ 254.7k
Jeanette Bjorkquist
Principal Financial Officerless than a yearno data0.014%
€ 69.7k
Shannon Ryan
Senior Vice President of Investor Relationsno datano datano data
Jennifer Troia
Chief Human Resources Officer8yrsno datano data
Anuj Gaggar
Chief Medical Officer2yrsno datano data
Katie Kitrinos
Senior VP of Preclinical Research & Developmentless than a yearno datano data
Thomas Rollins
Executive Officer7.6yrsUS$652.02kno data
Amy Figueroa
Investor Relations Consultantno datano datano data
4.1yrs
Average Tenure
48yo
Average Age

Experienced Management: V7B's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jason Okazaki
CEO, President & Director2.8yrsUS$1.77m0.089%
€ 459.4k
Anthony Altig
Independent Director13.8yrsUS$96.75k0.0042%
€ 21.7k
William Ringo
Independent Non-Executive Chairman11.3yrsUS$139.25k0.0092%
€ 47.4k
John McHutchison
Director6.3yrsUS$81.75k0.10%
€ 540.7k
Michael Houghton
Independent Director4.3yrsUS$76.75k0.020%
€ 104.3k
Susan Mahony
Independent Director7.9yrsUS$91.75k0%
€ 0
Gina Consylman
Independent Director5.1yrsUS$89.25k0%
€ 0
Lisa Johnson-Pratt
Independent Director4.5yrsUS$81.75k0%
€ 0
Tomas Cihlar
Director1.9yrsno datano data
Robert Cook
Director1.7yrsno datano data
4.8yrs
Average Tenure
63.5yo
Average Age

Experienced Board: V7B's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 12:39
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Assembly Biosciences, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.
Irina Rivkind KofflerCantor Fitzgerald & Co.